Abstract
Biotechnology applied to pharmaceuticals has made significant contributions to medicine during the past 20 years. Although important products will continue to emerge, benefiting patients and perhaps lowering medical costs, there are too many biopharmaceutical companies chasing too few products, which are themselves over-regulated and incredibly expensive to test and bring to market.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
206,07 € per year
only 17,17 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Altman, L. US Unit backs human insulin for the market. New York Times 1 (October 30, 1982).
Boston Consulting Group. The Contribution of Pharmaceutical Companies: What's at Stake for America (Boston Consulting Group, Boston, September 1993).
Peck, C. C. Drug development: improving the process. Food Drug Law J. 52, 163–167 (1997).
Tufts center for the Study of Drug Development. Outlook 2002 (Tufts Center for the Study of Drug Development, Boston, 2002).
Miller, H. I. To America's Health: A Proposal to Reform the Food and Drug Administration (Hoover Institution Press, Stanford, California, 2000).
Shlaes, D. M. & Moellering, R. C. The US Food and Drug Administration and the end of antibiotics. Clin. Infect. Dis. 34, 420–423 (2002).
Grabowski, H. G. & Vernon, J. M. The Regulation of Pharmaceuticals (American Enterprise Institute for Public Policy Research, Washington DC, 1983).
Zimm, A. Psoriasis drug delay sinks firms' shares. San Jose Mercury News C1 (April 6, 2002).
Jaffe, S. Biotech–big pharma betrothals declining. The Scientist 57–58 (July 8, 2002).
Anon. Global Pharmaceutical Company Partnering Capabilities Survey. PricewaterhouseCoopers [online] (cited 13 Aug 2002) <http://www.pwcglobal.com > (2000).
Knight, J. Biotech woes set to hit academics. Nature 418, 5 (2002).
Author information
Authors and Affiliations
Related links
Related links
DATABASES
LocusLink
FURTHER INFORMATION
Biotechnology Industry Organization
Rights and permissions
About this article
Cite this article
Miller, H. As biotech turns 20.... Nat Rev Drug Discov 1, 1007–1008 (2002). https://doi.org/10.1038/nrd965
Issue Date:
DOI: https://doi.org/10.1038/nrd965
